AbbVie makes medicines for chronic diseases, the kind patients take month after month, year after year. Its biggest earner right now is Skyrizi, which treats autoimmune diseases like psoriasis and Crohn's disease. Rinvoq treats similar conditions. Botox treats both medical problems like chronic migraine and cosmetic concerns like frown lines. Vraylar treats schizophrenia and bipolar disorder. Because patients with these conditions need ongoing treatment, AbbVie earns revenue repeatedly from the same patients rather than from one-time purchases. The company sells to wholesalers, specialty pharmacies, hospitals, and government agencies, and it competes fiercely with other drug companies in every one of these markets. The diagram below traces where the money goes.
How AbbVie Makes Money
flowchart LR
A["Drug Discovery &
Development"] --> B["Four Product
Portfolios"]
B --> C["Global Sales &
Distribution"]
C -->|"$61.2B Revenue"| D["Gross Profit
70.2% margin"]
D --> E["Operating Income
24.6% margin"]
E --> F["Operating Cash Flow
$19.0B"]
F --> G["Free Cash Flow
$17.8B"]
G -->|"Reinvestment"| A
G -->|"Debt Service"| H["Net Debt
$56.2B"]
C -->|"Prescription
Volume"| B
B -->|"Patent &
Exclusivity"| C
Five years of financial data tell a story with two very different chapters. From 2021 to 2022, revenue grew from $56.2 billion to $58.1 billion, and free cash flow was strong at $24.2 billion. Then in 2023, revenue dipped to $54.3 billion. The reason was Humira. After losing its patent protection, cheaper copycat versions called biosimilars entered the market. Humira had been AbbVie's biggest product for years. Its U.S. revenue fell from $12.2 billion in 2023 to $7.1 billion in 2024, then to $3.1 billion in 2025. That collapse was enormous. But Skyrizi and Rinvoq were growing fast enough to absorb the hit.
AbbVie Annual Revenue ($ Billions)
Revenue dipped in 2023 as Humira faced biosimilar competition, then recovered as Skyrizi and Rinvoq took over growth duties.
By 2025 total revenue reached $61.2 billion, the highest in this five-year period. Skyrizi alone brought in $17.6 billion, up 50% from the year before. Rinvoq added $8.3 billion, up 39%. Together those two drugs made up 42% of total revenue in 2025. The company pulled off what few pharmaceutical companies manage: replacing a blockbuster drug before the hole it left became a crisis. Gross margin held steady at around 70% in both 2024 and 2025, recovering from a dip to 62% in 2023. That dip happened partly because the Humira decline hit revenue faster than costs could be cut.
$7.8B
Skyrizi Revenue 2023
$17.6B
Skyrizi Revenue 2025
Skyrizi more than doubled in two years, becoming the engine that replaced Humira's lost revenue.
Free cash flow tells a more complicated story. It was $24.2 billion in 2022, then stayed around $22 billion in 2021 and 2023. But it dropped to $17.8 billion in both 2024 and 2025. Net debt rose sharply too, from $39.4 billion in 2023 back up to $54.8 billion in 2024 and $56.2 billion in 2025. The reason is acquisitions. AbbVie paid $18.5 billion in cash in 2024 to buy ImmunoGen, a cancer drug company, and Cerevel Therapeutics, a brain disease company. In 2025 it spent billions more on deals including acquiring Capstan Therapeutics and Gilgamesh Pharmaceuticals. The company is betting that buying new pipeline drugs now will keep revenue growing after today's top products eventually face their own patent cliffs.
$11.7B
Cash dividends paid to shareholders in 2025, even as the company carried $56.2B in net debt
What Is a Patent Cliff?
A pharmaceutical patent gives a drug company the exclusive right to sell a medicine for a limited period. When that patent expires, other companies can make cheaper copies called generics or biosimilars. Sales of the original drug can fall very fast, sometimes by half or more within a few years. This is called a patent cliff. Drug companies try to replace lost revenue by launching new drugs before the cliff arrives.
The risks AbbVie faces are specific and documented. First, the U.S. government now has the legal power to set Medicare prices for certain drugs. Four AbbVie products have already been picked: Imbruvica starting in 2026, Vraylar and Linzess starting in 2027, and Botox starting in 2028. More products could be selected in future years. Second, Skyrizi and Rinvoq's core composition-of-matter patents expire in 2033, though AbbVie has settled with generic manufacturers to delay U.S. generic entry for Rinvoq until at least April 2037. Skyrizi's timeline is less certain. Third, a small number of pharmacy benefit managers, which are the companies that decide which drugs insurance will cover, can remove AbbVie products from coverage lists or demand larger discounts with little warning.
42%
Share of AbbVie's 2025 total revenue coming from just two drugs: Skyrizi and Rinvoq
What Are Pharmacy Benefit Managers?
Pharmacy benefit managers, often called PBMs, are companies that manage prescription drug benefits on behalf of insurance plans. They decide which drugs get covered, at what price, and how easily patients can access them. A handful of very large PBMs control access to most insured patients in the United States. If a PBM drops a drug from its coverage list, sales can fall sharply and quickly.
There is also a supply chain risk that sits quietly in the background. AbbVie relies on single suppliers for some raw materials. If one of those suppliers fails a regulatory inspection or simply cannot deliver, AbbVie could face product shortages. Finding a replacement supplier takes time and requires regulatory approval, which means the disruption could last months. None of these risks is speculative. Each one is a documented, active threat to the revenue line.
2024
milestone
AbbVie Spends $18.5B to Rebuild Its Pipeline
After Humira lost patent protection and biosimilar competitors flooded the market, AbbVie moved aggressively to fill its future pipeline. It acquired ImmunoGen for its cancer drug Elahere and Cerevel Therapeutics for its neuroscience assets. This pushed net debt back above $54 billion and cut free cash flow from $22 billion to $17.8 billion. The logic was clear: spend now to avoid another Humira-sized gap later.
AbbVie's pipeline now includes approximately 90 compounds or indications in development, with around 60 in mid- or late-stage trials. The company is expanding Rinvoq into new conditions like alopecia areata and vitiligo, pursuing a Parkinson's disease drug called tavapadon, and developing a new type of botulinum toxin called TrenibotE that works faster but wears off sooner than standard Botox. Whether these pipeline bets pay off will determine whether AbbVie can repeat what it did with Skyrizi and Rinvoq: grow new drugs fast enough to replace the ones that lose exclusivity.
AbbVie pledged $100 billion in U.S.-based research, development, and manufacturing investment over the next decade, and reached a voluntary agreement with the U.S. government that includes a three-year exemption from tariffs and future price mandates. That deal may buffer some near-term pricing pressure, but it also signals how much regulatory scrutiny pharmaceutical pricing now attracts.
The Bet
Skyrizi and Rinvoq keep growing fast enough, for long enough, to fund the next generation of drugs before their own patents run out around 2033. AbbVie executed this replacement once already, swapping Humira for Skyrizi and Rinvoq as Humira collapsed. The assumption embedded in the current model is that AbbVie can do it again, that the pipeline drugs being acquired and developed today will be ready to carry revenue before Skyrizi and Rinvoq face the same biosimilar pressure Humira now faces. If the pipeline disappoints or government price controls bite deeper than expected, the two drugs now generating 42% of all revenue have no obvious successor at the scale needed.
Open question
AbbVie proved it could survive the Humira cliff by building Skyrizi and Rinvoq into blockbusters. Now those two drugs are the foundation, and the clock on their exclusivity is already running. The company is spending heavily on acquisitions and pipeline development to build the next layer, while simultaneously paying $11.7 billion a year in dividends and carrying $56.2 billion in net debt. Can AbbVie find and build a third generation of blockbusters fast enough to stay ahead of the patent cycle, or does the model require everything to go right at once: continued Skyrizi and Rinvoq growth, successful pipeline execution, manageable government price controls, and stable debt loads, all at the same time?
Compiled · 10-K · FY2025
Patent Expiration and Generic Competition
Skyrizi and Rinvoq together made up 42% of AbbVie's total revenue in 2025. When patents on these major products expire, generic and biosimilar competitors can enter the market and quickly take away sales. Patent challenges and government compulsory licensing could force AbbVie to lose exclusivity earlier than expected.
Government Price Controls
The Inflation Reduction Act lets the U.S. government set Medicare prices for certain drugs as early as 9 years after FDA approval. Four AbbVie products have already been selected for price controls (Imbruvica starting 2026, Vraylar and Linzess starting 2027, and Botox starting 2028), and more could be selected in the future, significantly reducing revenues.
Pharmacy Benefit Manager Control
A small number of pharmacy benefit managers control which drugs patients can access through insurance. These intermediaries can exclude AbbVie products from insurance coverage, require prior approval steps, or demand higher rebates with little warning, which could reduce patient access and sales volumes.
Product Pipeline Dependency on Third Parties
AbbVie depends on collaborations with other companies for part of its drug development pipeline. If these partners fail to meet their obligations or disputes arise over intellectual property rights, it could delay or prevent new products from reaching the market.
Supply Chain Concentration
AbbVie relies on single suppliers for some raw materials and components used in manufacturing. If a supplier fails to deliver, faces regulatory problems, or experiences disruptions, AbbVie could experience product shortages and lost revenue. Finding alternative suppliers requires time and regulatory approval.
10-K Item 1A · Risk Factors
